Connect with us
Epidiolex reports positive results for its drug when treating tuberous sclerosis complex (TSC) a rare genetic condition. The condition causes mostly benign tumors to grow in...
Ireland-based Jazz Pharmaceuticals (Nasdaq: JAZZ), the makers of Epidiolex, reported net income in the third quarter this year of $215 million, with revenue up 9% year-over-year....
The Daily Hit is a recap of the top financial news stories for Thursday, September 5, 2024. On the Site Longtime New Mexico cannabis company shuttering...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced plans to present eight abstracts at an upcoming major conference in Europe, showcasing new data on its cannabidiol (CBD) epilepsy...
